ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 12 Jul 2022
Last Updated on 12 Jul 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has not recommended ruxolitinib 5 mg tablet for listing on the Medication Assistance Fund (MAF) for treating patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea, in view of low clinical need, and uncertain clinical and cost-effectiveness compared with subsidised alternatives.

Clinical indication, subsidy class and MediShield Life claim limit for ruxolitinib are provided in the Annex.


Ruxolitinib for treating polycythaemia vera (12 Jul 22) Ruxolitinib for treating polycythaemia vera PES (12 Jul 22)